Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Australian Clinical Labs Ltd ( (AU:ACL) ) just unveiled an announcement.
Australian Clinical Labs Ltd announced the issuance and conversion of unquoted equity securities, specifically 15,662 ordinary fully paid shares. This move is part of the company’s ongoing financial management and could impact its capital structure, potentially influencing its market positioning and stakeholder interests.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, providing pathology services and diagnostic testing. The company focuses on delivering high-quality medical testing services across Australia, catering to both public and private healthcare sectors.
Average Trading Volume: 927,021
Technical Sentiment Signal: Sell
Current Market Cap: A$536.1M
See more insights into ACL stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue